Subscribe to our RSS feeds RSS | Login | Register  
 

Cambridge BioMarketing

Company: Cambridge BioMarketing

Address Details

245 First Street
12th Floor
Cambridge, MA 02142
 

Contact Details

Phone: 617-225-0001
Fax: 617-225-0988
 
 
Founded: 2002

Officers: Steve West, CEO and Chief Creative Officer; Sue R. Levy, Partner, Group Account Director; Scott Dubow, Partner, Direct Marketing Leader; Sean Welsh, Partner, Creative Director/Art; Mike Hodgson, Partner, Creative Director/Copy; Jim Elgart, Partner, Chief Financial Officer. Healthcare accounts: Alexion Pharmaceuticals: Soliris; Acorda Therapeutics: Fampridine-SR; TolerX: Otelixizumab; Medtronic Diabetes: diabetes market development; TogetherRX Access LLC: TogetherRX Access program; Vertex Pharmaceuticals: Telaprevir pre-launch marketing; Novartis Oncology: corporate; Novartis Vaccines & Diagnostics: corporate; Novartis Access: corporate; Novartis Institutes for BioMedical Research: corporate; McKesson Corporation: corporate marketing; JDRF (Juvenile Diabetes Research Foundation): pro bono.

Accounts gained (8): Acorda Therapeutics: Fampridine-SR; Alexion Pharmaceuticals: Soliris; Vertex Pharmaceuticals: Telaprevir pre-launch marketing; Medtronic Diabetes: diabetes market development; Novartis Oncology: corporate; Novartis Vaccines & Diagnostics: corporate; Novartis Access: corporate; JDRF (Juvenile Diabetes Research Foundation): pro bono.

Accounts lost (1): Shire Human Genetic Therapies: Elaprase.



U.S. billings breakdown by media/source:

Medium 20072006
Professional Ads 15.0%20.0%
Direct Marketing30.0%30.0%
Sales materials20.0%20.0%
DTC Print5.0%5.0%
DTC broadcast10.0%10.0%
Digital marketing20.0%15.0%


Featured Work
Product: Soliris
Client: Alexion Pharmaceuticals
Creative/account team: Sean Welsh, Partner, Creative Director/Art; Hannah Lavon, Graphic Designer; Mike Hodgson, Partner, Creative Director/Copy; Sue R. Levy, Partner, Group Account Director; Shauna Horvath, Account Supervisor.
Media team: Compas, Inc.
Why this ad is special: Soliris is an orphan drug for a rare blood neoplasia, PNH, that must compete for attention with the Hem/Onc audience. The ad distills problem, solution, and call to action into a simple, telegraphic, and memorable graphic and headline.